Safety of Topical Dermatologic Medications in Pregnancy

July 2016 | Volume 15 | Issue 7 | Original Article | 830 | Copyright © July 2016


Viral M. Patel BS, Robert A. Schwartz MD MPH DSc (Hon), and W. Clark Lambert MD PhD

Rutgers New Jersey Medical School, Newark, NJ

  1. Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J of Dermatol. 2011;165:943-952.
  2. Pennsaid [package insert]. Varennes, Quebec: Nuvo Manufacturing; 2009.
  3. Voltaren [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2009.
  4. Briggs G. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 10th ed: Lippincott Williams & Wilkins. 2014.
  5. Cassina M, De Santis M, Cesari E, et al. First trimester diclofenac exposure and pregnancy outcome. Reprod Toxicol. 2010;30:401-404.
  6. Torloni MR, Cordioli E, Zamith MM, et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound Obstet Gynecol. 2006;27:227-229.
  7. Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG. 2013;120:948-959.
  8. Akturk S, Celebi ZK, Erdogmus S, et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. Transplant Proc. 2015;47:1442-1444.
  9. Hebert MF, Zheng S, Hays K, et al. Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum. Transplantation. 2013;95:908-915.
  10. Armenti VT, Moritz MJ, Cardonick EH, et al. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs. 2002;62:2361-2375.
  11. Schaefer C, Peters P, Miller R. Drugs during pregnancy and lactation. 3rd ed: Academic Press. 2014.
  12. Elidel [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; 2006.
  13. Mattison D. Clinical pharmacology during pregnancy. 1st ed: Academic Press. 2012.
  14. Efudex [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; 2005.
  15. Tyler KH. Dermatologic therapy in pregnancy. Clin Obstet Gynecol. 2015;58:112-118.
  16. Al Hammadi A, Al-Haddab M, Sasseville D. Dermatologic treatment during pregnancy: practical overview. J Cutan Med Surg. 2006;10:183-192.
  17. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24:167-197
  18. Dovonex [package insert]. Parsippany, NJ: Leo Pharma; 2015.
  19. Tauscher AE, Fleischer AB, Jr., Phelps KC, et al. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6:561-570.
  20. Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53:S59-69.
  21. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:459-477.
  22. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70:401 e401-414; quiz 415.
  23. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997;37:S55-58.
  24. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002;46:900-906.
  25. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008;59:295-315.
  26. Drithocreme [package insert]. Mississauga, Ontario: Summers Laboratories; 2012.
  27. Anderson B, de Peyster A, eds. Encyclopedia of Toxicology. 2nd ed: Academic Press; 2005.
  28. USDHHS. Toxicological Profile for Wood Creosote, Coal Tar Creosote, Coal Tar, Coal Tar Pitch, and Coal Tar Pitch Volatiles. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry 2002.
  29. Roelofzen JHJ, Aben KKH, Oldenhof UTH, et al. No Increased Risk of Cancer after Coal Tar Treatment in Patients with Psoriasis or Eczema. J Invest Dermatol. 2010;130:953-961.
  30. Franssen ME, van der Wilt GJ, de Jong PC, et al. A retrospective study of the teratogenicity of dermatological coal tar products. Acta Derm Venereol. 1999;79:390-391.
  31. Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol. 2009;61:294-302.
  32. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43:S31-35.
  33. Tazorac [package insert]. Irvine, CA: Allergan; 2014.
  34. Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218-220.
  35. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32:505-506.
  36. Colley SM, Walpole I, Fabian VA, et al. Topical tretinoin and fetal malformations. Med J Aust. 1998;168:467.
  37. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341:1352-1353.
  38. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136:117-121.
  39. Retin-A [package insert]. Los Angeles, CA: Ortho Dermatological.
  40. Berard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63:196-205.
  41. Maloney ME, Stone SP. Isotretinoin and iPledge: a view of results. J Am Acad Dermatol. 2011;65:418-419.
  42. Shin J, Cheetham TC, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol. 2011;65:1117-1125.
  43. Differin [package insert]. Fort Worth, TX: Galderna; 2012.
  44. Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350:339.
  45. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473-492.
  46. Wolf K, Silapunt S. The use of sodium sulfacetamide in dermatology. Cutis. 2015;96:128-130.
  47. Sodium sulfacetamide [package insert]. San Antonio, TX: BioComp Pharma.
  48. Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother. 1996;30:935-940.
  49. Schwarb F, Gabard B, Rufli T, et al. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology. 1999;198:44-51.
  50. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197-203.
  51. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
  52. Fluhr J, Degitz K. Antibiotics, azelaic acid and benzoyl peroxide in topical acne therapy. J Dtsch Dermatol Ges. 2010;8:S24-30.
  53. Shapiro J. Safety of topical minoxidil solution: a one-year, prospective, observational study. J Cutan Med Surg. 2003;7:322-329.
  54. Smorlesi C, Caldarella A, Caramelli L, et al. Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Res A Clin Mol Teratol. 2003;67:997-1001.
  55. Rojansky N, Fasouliotis SJ, Ariel I, et al. Extreme caudal agenesis. Possible drug-related etiology? J Reprod Med. 2002;47:241-245.
  56. Leuschner J. Reproductive toxicity studies of D-camphor in rats and rabbits. Arzneimittel-Forschung. 1997;47:124-128.
  57. Alakilli SY. Evaluation of camphor mutagenicity in somatic cells of pregnant rats. Asian J Biotech. 2009;1:111-117.
  58. Weiss J, Catalano P. Camphorated oil intoxication during pregnancy. Pediatrics. 1973;52:713-714.
  59. Heinonen O, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy: Maternal Drug Exposure and Congenital Malformations. Littleton, MA: Publishing Sciences Group. 1977.
  60. Roth MM. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol. 2011;12:25-41.
  61. Gallo M, Sarkar M, Au W, et al. Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. Arch Intern Med. 2000;160:3141-3143.
  62. Ardjomand-Woelkart K, Bauer R. Review and Assessment of Medicinal Safety Data of Orally Used Echinacea Preparations. Planta Med. 2015.
  63. Barcz E, Sommer E, Nartowska J, et al. Influence of Echinacea purpurea intake during pregnancy on fetal growth and tissue angiogenic activity. Folia Histochem Cytobiol. 2007;45:35-39.
  64. Dante G, Bellei G, Neri I, et al. Herbal therapies in pregnancy: what works? Curr Opin Obstet Gynecol. 2014;26:83-91.

AUTHOR CORRESPONDENCE

Robert A. Schwartz MD MPH DSc (Hon)……............................. roschwar@cal.berkeley.edu
Close Menu